Clinical results from a 127-patient sub-study of the Circulating Cell-free Genome Atlas (CCGA) trial show Grail Inc. genome-sequencing blood-tests can detect lung cancer with 98% specificity and up to 92% sensitivity.
A pre-planned sub-study of CCGA is evaluating three of Grail's prototype genome-sequencing blood-based assays for early cancer detection. CCGA is a prospective, observational, longitudinal study of 15,000 people with and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?